Uterine Cervical Neoplasms Clinical Trial
Official title:
Feasibility of ReSpace™ Hydrogel to Establish a Stable Cervical-rectal Space
Verified date | October 2023 |
Source | Peking Union Medical College Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
In this study, 5 subjects will be enrolled and the cumulative D2cc dose for rectum during brachytherapy will be recorded as the primary outcome measures.
Status | Completed |
Enrollment | 8 |
Est. completion date | October 10, 2023 |
Est. primary completion date | October 10, 2023 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: - Patients with pathologically confirmed cervical cancer who must be scheduled to undergo radical radiotherapy by means of intensity-modulated radiotherapy combined with 3D brachytherapy. - Karnofsky score = 70. - Subjects aged = 18 years and = 75 years. - Subjects must be able to cooperate in completing the entire study. - The subjects' pelvic and abdominal cavity and joints are free of metal implants and can tolerate MRI. - No contraindications to CT scanning. - Subjects must be able to understand the purpose of the trial, voluntarily participate and sign an informed consent form. Exclusion Criteria: - Subjects who have received prior pelvic radiotherapy. - Subjects whose target tumors have been previously treated (chemotherapy, immunotherapy, surgical treatment, etc.) - Subjects with other primary malignancies - Subjects with contraindications to radiotherapy, as determined by the investigators - Subjects with injection site infections. - Subjects who are allergic to the ingredients of the device. - Subjects whose tumors invade the injection site and affect the injection process and injection safety, as determined by the investigators - Persons with severe mental illness, cognitive impairment and thinking disorders. - Participants in other drug clinical trials or medical device clinical trials 1 month prior to screening - Pregnant or lactating women or those who plan to get pregnant within the last six months - Subjects who cannot be followed up as prescribed by the doctor - Other conditions that, in the judgment of the investigator, make the subject unsuitable for enrollment |
Country | Name | City | State |
---|---|---|---|
China | Peking Union Medical College Hospital | Beijing |
Lead Sponsor | Collaborator |
---|---|
Peking Union Medical College Hospital | Shanghai Reunion Biotech Co.,Ltd. |
China,
de Freitas AC, Gurgel AP, Chagas BS, Coimbra EC, do Amaral CM. Susceptibility to cervical cancer: an overview. Gynecol Oncol. 2012 Aug;126(2):304-11. doi: 10.1016/j.ygyno.2012.03.047. Epub 2012 Apr 4. — View Citation
Kashihara T, Murakami N, Tselis N, Kobayashi K, Tsuchida K, Shima S, Masui K, Yoshida K, Takahashi K, Inaba K, Umezawa R, Igaki H, Ito Y, Kato T, Uno T, Itami J. Hyaluronate gel injection for rectum dose reduction in gynecologic high-dose-rate brachytherapy: initial Japanese experience. J Radiat Res. 2019 Jul 1;60(4):501-508. doi: 10.1093/jrr/rrz016. — View Citation
Peach MS, Moore J, Giles W, Trainor J, Long T, Moon N, Hylton JE, Showalter TN, Libby B. Development and preclinical testing of a novel biodegradable hydrogel vaginal packing technology for gynecologic high-dose-rate brachytherapy. J Contemp Brachytherapy. 2018 Aug;10(4):306-314. doi: 10.5114/jcb.2018.77952. Epub 2018 Aug 31. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The cumulative D2cc dose for rectum during brachytherapy | The mean of the cumulative rectum D2cc dose during brachytherapy will be calculated for subjects. which will be used to validate the parameter selection for phase II sample size estimation. | 21 days post index procedure | |
Secondary | Implantation success rate of hydrogel spacer | The success rate of hydrogel spacer implantation will be evaluated by the investigator for subjects. | during procedure | |
Secondary | Evaluation of device performance of hydrogel spacer | The ease of use of the test device will be evaluated by the investigator on the day of Operation. The evaluation items are as follows:
Whether the device is easy to assemble. Whether the process of positioning the needle is smooth and whether it is easy to position the needle. Whether the device is easy to inject and whether the injection process is smooth. |
during procedure | |
Secondary | Injection volume of hydrogel spacer | Recording the amount of hydrogel spacer injected in the subjects,which will be used to evaluate the reasonableness of the injected dose of ReSpace™ when hydrogel is injected between the rectum and cervix in women undergoing radiation therapy. | during procedure |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT03225443 -
Observation and Evaluation of Short-term Curative Effect of Local Advanced Cervical Cancer Treated With Particle Radiotherapy Versus Neoadjuvant Chemotherapy
|
N/A | |
Recruiting |
NCT01373723 -
Economic Evaluation of Three Populational Screening Strategies for Cervical Cancer
|
N/A | |
Terminated |
NCT01234480 -
Intended Use Study of the BD SurePath Plus™ Pap
|
||
Terminated |
NCT01194609 -
A Pilot Study of Radiation-Immune Cell Combination Therapy in Cervical Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT02808832 -
An HPV Vaccine Provider Intervention in Safety Net Clinics
|
N/A | |
Completed |
NCT01014026 -
Self-sampling and Human Papillomavirus (HPV)-Testing for Unscreened Women in Cervical Cancer Prevention
|
Phase 3 | |
Terminated |
NCT01075412 -
FLT PET Imaging for Cervical Cancer
|
Phase 2 | |
Completed |
NCT02865889 -
Cost-Effectiveness and Patients Satisfaction of Conventional vs Robotic-Assisted Laparoscopy in Gynecologic Oncologic Indications
|
N/A | |
Completed |
NCT00377845 -
Cervix Cytological Screening - Comparison of Tampon Self-Test and the Routine Smear.
|
Phase 0 | |
Recruiting |
NCT05531981 -
Detection of Minimal Residual Disease Based on HPV ctDNA in Cervical Cancer
|
||
Recruiting |
NCT05393440 -
First-in-human (FIH) Phase I Trial of BS-006 in Cervical Cancer
|
Phase 1 | |
Recruiting |
NCT05007106 -
MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)
|
Phase 2 | |
Completed |
NCT02866006 -
Safety and Tolerability Evaluation Study of BVAC-C in Patients With HPV Type 16 or 18 Positive Cervical Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03270995 -
Cognitive-Existential Group Therapy to Reduce Fear of Cancer Recurrence: A RCT Study
|
N/A | |
Completed |
NCT02320578 -
2D Versus 3D Radical Laparoscopic Hysterectomy for Cervical Cancer: a Prospective Randomized Trial
|
N/A | |
Terminated |
NCT02900248 -
CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice
|
||
Not yet recruiting |
NCT05065853 -
Urinary and Vaginal HPV Testing in Cervical Cancer Screening
|
||
Completed |
NCT01231945 -
Low-Cost Molecular Cervical Cancer Screening Study
|
N/A | |
Completed |
NCT01717391 -
[F-18] Fluorothymidine PET/CT Imaging for Pelvic Cancers
|
Phase 2 | |
Active, not recruiting |
NCT04947605 -
Epidemiological Landscape of Cervical Cancer in Latin America
|